Sharsti Sandall

Sharsti Sandall, PhD, has spent the last 10+ years at Seagen (now Pfizer) where she has initiated, led, and helped develop many cancer therapeutics. She is a passionate and effective scientific leader that utilizes her deep cell biology background to design and better understand cancer therapeutics. In her current position, she is a Sr. Director in the Research Department overseeing the research for all the Pfizer antibody-drug conjugates (ADCs) that are in clinical development. Prior to joining Seagen she was a Damon Runyon Postdoctoral Fellow studying the adult tissue stem cell niche at the Salk Institute for Biological Studies. She earned her BS in Microbiology from California State University, Long Beach and her PhD in Biomedical Sciences from the University of California, San Diego where she studied mechanisms of mitotic spindle function. In her spare time, she loves spending time outdoors with her family and dog, especially skiing, boating, surfing, and running.